Endogena Therapeutics Inc. is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena’s approach can potentially change how degenerative conditions related to aging and genetic disorders are treated. The concept is based on selective regulation of endogenous adult stem- and progenitor cells for controlled tissue repair by small molecules. Endogena’s most advanced programs target degenerative diseases of the eye, including retinitis pigmentosa and geographic atrophy (secondary to AMD). Endogena is registered in San Francisco, USA, with a head office in Zürich, Switzerland, and a research facility at JLABS in Toronto, Canada.